Phase II randomized study of Folfiri vs Folfiri plus Celecoxib in first line treatment of advanced colorectal cancer (ACRC)

被引：0
|
作者：
Maiello, E.
Giuliani, F.
Romito, S.
Pezzella, G.
Mallamaci, R.
Di Renzo, G.
Di Bisceglie, M.
Gebbia, V.
Lopez, M.
Colucci, G.
机构：
[1] IRCCS, Inst Oncol, Med Expt Oncol Unit, Bari, Italy
[2] Cardarelli Hosp, Dept Oncol, Campobasso, Italy
[3] SS Annunziata Hosp, Dept Oncol, Taranto, Italy
[4] Reg Hosp, Oncol & Hematol Unit, Rionero In Vulture, Italy
[5] La Maddalena Hosp, Med Oncol Unit, Palermo, Italy
[6] IRE, Med Oncol Unit, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [1] Phase II randomized study of FOLFIRI vs FOLFIRI plus celecoxib in first line treatment of advanced colorectal cancer (ACRC).
    Maiello, E
    Giuliani, F
    Romito, S
    Pezzella, G
    Mallamaci, R
    Di Renzo, N
    Di Bisceglie, M
    Gebbia, V
    Lopez, M
    Colucci, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 284S - 284S
  • [2] CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)
    Van Cutsem, E.
    Bodoky, G.
    Kyung Roh, J.
    Folprecht, G.
    Park, Y. S.
    Van Laethem, J. L.
    Raoul, J. L.
    Ciardiello, F.
    Lebrun, P.
    Rougier, P.
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 235
  • [3] A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
    Santoro, A.
    Comandone, A.
    Rimassa, L.
    Granetti, C.
    Lorusso, V.
    Oliva, C.
    Ronzoni, M.
    Siena, S.
    Zuradelli, M.
    Mari, E.
    Pressiani, T.
    Carnaghi, C.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1888 - 1893
  • [4] FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)
    Maiello, E.
    Giuliani, F.
    Gebbia, V.
    Di Renzo, N.
    Pezzella, G.
    Romito, S.
    Mallamaci, R.
    Lopez, M.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII55 - VII59
  • [5] Folfiri-bevacizumab as first line treatment for advanced colorectal cancer (ACRC): Results from 77 consecutive unsellected patients
    Ruiz de Lobera, A.
    Mane, J. M.
    Lopez-Vivanco, G.
    Munoz, A.
    Lopez de Argumedo, G.
    Ferreiro, J.
    Diaz de Corcuera, I.
    Fuente, N.
    Moreno, A.
    Rubio, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] FINAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB PLUS FOLFIRI VS. PLACEBO PLUS FOLFIRI IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Carrato, A.
    Swieboda-Sadlej, A.
    Staszewska-Skurczynska, M.
    Lim, R.
    Roman, L.
    Shparyk, Y.
    Bondarenko, I.
    Lin, X.
    Lechuga, M. J.
    Tursi, J. M.
    Sun, Y.
    De la Cruz, J. A.
    Jonker, D.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 19 - 19
  • [7] Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
    Wainberg, Zev A.
    Boccia, Ralph V.
    Strickler, John H.
    Moehler, Markus H.
    Sirard, Cynthia A.
    Walsh, Erin K.
    Parker, Elizabeth C.
    Lee, Keun-Wook
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS275 - TPS275
  • [8] First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study
    Tsuji, Yasushi
    Satoh, Taroh
    Tsuji, Akihito
    Muro, Kei
    Yoshida, Motoki
    Nishina, Tomohiro
    Nagase, Michitaka
    Komatsu, Yoshito
    Kato, Takeshi
    Miyata, Yoshinori
    Mizutani, Naoko
    Hashigaki, Satoshi
    Lechuga, Maria Jose
    Denda, Tadamichi
    CANCER SCIENCE, 2012, 103 (08) : 1502 - 1507
  • [9] Folfiri as second-line treatment in advanced pancreatic cancer: A phase II study
    Giuliani, F.
    Mallamaci, R.
    Di Bisceglie, M.
    Galetta, D.
    Colucci, G.
    ANNALS OF ONCOLOGY, 2006, 17 : VII158 - VII158
  • [10] Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Lordick, F.
    Rong, A.
    Gansert, J.
    EJC SUPPLEMENTS, 2009, 7 (03): : 10 - 10
12345